Objective-Abnormal proliferation and migration of vascular smooth muscle cells (VSMCs) are critical events in the progression of several vasculopathologies. Adenosine monophosphate-activated protein kinase (AMPK) has been shown to play a pivotal role in cellular proliferation and migration. However, the roles of AMPK in VSMC migration and its underlying molecular mechanisms remain elusive. Approach and Results-VSMC migration and the neointima formation were studied in cultured mouse VSMCs or in carotid artery ligation of wild-type C57BL/6J mice, AMPKα2, AMPKα1 homozygous-deficient (AMPKα2 −/− , AMPKα1 −/− ) mice. Deletion of AMPKα2, but not AMPKα1, led to increased phosphorylation of both IкB kinase α and its downstream target nuclear factor кB2/p100 at serine 866/870. Consequently, phosphor-p100 at S866/870 bound with E3 ubiquitin ligase β-transducin repeat-containing protein resulting in the proteolytic processing of the p100 precursor and nuclear factor кB2/p52 induction. Interestingly, acetylation of histone H3 at lysine 56 mediated by histone deacetylase-3 reduction was enhanced significantly in AMPKα2 −/− VSMCs compared with wild-type or AMPKα1 −/− VSMCs. Moreover, the augmented association of p52/acetylation of histone H3 at lysine 56 with the promoter of ubiquitin E3 ligase, S-phase kinase-associated protein 2, was shown in AMPKα2 −/− VSMCs by chromatin immunoprecipitation assay. Furthermore, AMPKα2 deletion caused S-phase kinase-associated protein 2-mediated E-cadherin downregulation. S-Phase kinaseassociated protein 2 siRNA abolished the increased migration of AMPKα2 −/− VSMCs via E-cadherin upregulation. Finally, neointima formation after ligation of carotid artery was increased in AMPKα2 −/− , but not AMPKα1 −/− , mice.
A bnormal proliferation and migration of vascular smooth muscle cells (VSMCs) play a critical role in various cardiovascular diseases, including restenosis after coronary stenting or transplant vasculopathy, as well as atherosclerosis. 1, 2 Several molecules have been shown to regulate VSMC migration. For example, p27 Kip1 (p27) is required for rapamycin-mediated inhibition of VSMC migration. 3 In addition, heme oxygenase-1 impedes platelet-derived growth factor (PDGF)-induced human VSMC migration through vascular endothelial growth factor A/vascular endothelial growth factor receptor-2 upregulation and consequent assembly of inactive vascular endothelial growth factor receptor-2/platelet-derived growth factor receptor β complexes. 4 However, the precise mechanisms that control VSMC migration remain poorly defined.
Adenosine monophosphate-activated protein kinase (AMPK), a key energy and redox sensor and regulator existing as a heterotrimeric complex with a catalytic subunit, α, and 2 regulatory subunits, β and γ, 5 exerts a cardiovascular protective function under physiological conditions and disease. 6 It has been reported that AMPK activation by 5-aminoimidazole-4-carboxamide ribonucleoside (AICAR) inhibits plateletderived growth factor-BB-induced or fetal calf serum-induced human VSMC proliferation significantly. 7 In addition, AMPK activation by AICAR inhibits angiotensin II-stimulated rat VSMC proliferation. 8 Moreover, deficiency of AMPKα2, but not AMPKα1, worsens neointima hyperplasia through p27 downregulation mediated by the upregulation of E3 ubiquitin ligase, S-phase kinase-associated protein 2 (Skp2) in VSMCs. 9 Interestingly, AMPK has been shown to control epithelial cell polarity and migration. 10, 11 For example, AMPK phosphorylates the microtubule plus end protein CLIP-170, which is required for microtubule dynamics and the regulation of directional cell migration. 12 Recently, AMPK activation was reported to inhibit VSMC migration via its regulation of cytoskeletal/focal adhesion/extracellular matrix stability. 13 However, how AMPK regulates VSMC migration and the relative contributions of different AMPKα isoform in VSMC migration had not been fully elucidated. In particular, the role of AMPK in epigenetic regulation has not been deeply explored.
Skp2, a well-characterized E3 ubiquitin ligase, is regulated both transcriptionally 9, 14 and post-translationally 15 and plays important roles in cell proliferation, 9, 16 differentiation, 17 and senescence. 18 In addition, cytoplasmic Skp2 augments cancer cell migration via ubiquitination and degradation of E-cadherin, 19 which exerts a critical role in cancer metastasis. 20, 21 It is reported that AMPKα2 deletion upregulates nuclear factor κB2 (NF-кB2)/p52, 9 a key transcription factor for Skp2. 22 However, the underlying mechanism is still unknown. Whether Skp2 is involved in AMPKα-mediated VSMC migration and the intrinsic mechanisms need to be clarified. Here, we show that the loss of AMPKα2, but not AMPKα1, upregulates NF-кB2 p52 via E3 ubiquitin ligase, β-transducin repeat-containing protein (β-TrCP)-mediated p100 proteolytic processing. Consequently, p52 and acetylated histone H3 at lysine 56 (AcH3-K56) are recruited to the promoter of Skp2, which mediates VSMC migration via E-cadherin downregulation.
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Materials and Methods
Materials and Methods are available in the online-only Supplement. [23] [24] [25] [26] 
Results
AMPKα2 Deficiency Enhances VSMC Migration Ex Vivo and In Vitro
First, we investigated the role of AMPKα in VSMC migration and whether this regulation is isoform specific. Aortic media sections isolated from WT, AMPKα2 −/− , and AMPKα1 −/− mice were cultured for 3 days. As shown in Figure 1A and 1B, AMPKα2 deletion increased the out-growing VSMCs number by 65% when compared with WT, which may be because of the enhanced VSMC proliferation and migration.
To determine the relative contributions of VSMC migration versus proliferation to the out-growing VSMCs, we measured the out-growing VSMC numbers in the presence of nocodazole (1×10 -7 mol/L), a proliferation inhibitor arresting cell cycle at G1/G2 phase, 27 for 3 days. As depicted in Figure 1D , nocodazole significantly blunted the out-growing VSMC numbers in both WT and AMPKα-deleted aortas. However, in nocodazoletreated aortic explants, VSMC numbers in AMPKα2-deleted aortas increased by only 26% when compared with WT ( Figure 1D ), indicating that enhanced VSMC migration was partially involved in aberrant out-growing VSMCs in AMPKα2deleted aortas. In line with our previous report, 9 VSMC proliferation increased by ≈39% in AMPKα2-deleted aortic explant.
We further used a transwell migration assay to test whether AMPKα2 deletion caused aberrant VSMC migration. As depicted in Figure 1E , cell migration was enhanced significantly in AMPKα2 −/− VSMCs. In addition, scratch wound assays with confluent and 48-hour serum-starved VSMCs, which would be Figure 2 . p52 induction in adenosine monophosphate-activated protein kinase-α2 (AMPKα2)-knockout vascular smooth muscle cells (VSMCs) is β-transducin repeat-containing protein (β-TrCP) mediated. A, Protein levels of phosphorylated p100 at Ser-866/870 (pp100-S866/870), p100, and p52 in wild-type (WT), AMPKα1 −/− , and AMPKα2 −/− mouse VSMCs. Top, pp100-S866/870, p100, and p52 protein levels were assessed by Western blot analysis. This blot is representative of 5 blots from 5 independent experiments. Bottom, Quantification of Western blot data. n=5; *P<0.01 vs WT. B, Increased phosphorylation of IκB kinase-α at Ser176 (pIкKα-S176) in AMPKα2 −/− VSMCs. Top, pIкKα-S176 and IкKα protein levels were assessed by Western blot. This blot is representative of 5 independent experiments. Bottom, Quantification of Western blot data. n=5; *P<0.01 vs WT. C, Enhanced interaction of p100 with pIкKα-S176 in AMPKα2 −/− VSMCs. Top, pIкKα-S176 was detected by immunoblotting with anti-pIкKα-S176 after immunoprecipitation (IP) with anti-p100. (Bottom) Quantification of coimmunoprecipitation data. n=4; *P<0.05 vs WT, by Kruskal-Wallis test followed by Dunn post hoc test. D and E, Augmented association of β-TrCP with pp100-S866/870 in AMPKα2 −/− VSMCs. pp100-S866/870 or β-TrCP was immunoprecipitated, and β-TrCP or pp100-S866/870 was detected by Western blot, respectively (n=4; *P<0.05 vs WT, by Kruskal-Wallis test followed by Dunn post hoc test). G0/G1 phase arrested, also demonstrated that AMPKα2 deletion increased the migrated VSMC number by ≈28% when compared with WT or AMPKα1 deletion ( Figure 1F-1H ). Taken together, these data indicate that AMPKα2, but not AMPKα1, is important in controlling VSMC migration.
p52 Induction in AMPKα2-Knockout VSMCs Is β-TrCP Mediated
We next investigated the molecular mechanisms by which AMPKα2 regulates VSMC migration. Because NF-кB2 p52 protein level is upregulated in AMPKα2 −/− , but not AMPKα1 −/− VSMCs, 9 we first determined how p52 was upregulated by AMPKα2 deletion. As depicted in Figure 2A , AMPKα2 deletion upregulated dramatically p100 phosphorylation at both Ser-866 and Ser-870 (pp100-S866/870), both of which are critical for the post-translational processing of p100 into p52. 28, 29 Accordingly, p52 was markedly upregulated in AMPKα2 −/− VSMCs when compared with WT or AMPKα1 −/− VSMCs (Figure 2A ). Furthermore, AMPKα2 deletion dramatically increased phosphorylation of IκB kinase-α at Ser176 ( Figure 2B ), a well-known active form of IκB kinase-α, 30 which is a key upstream kinase for p100 phosphorylation. 31 AMPKα2 deletion also caused an increased association of p100 with phosphorylated IκB kinase-α ( Figure 2C ). Reciprocal immunoprecipitation demonstrated that AMPKα2 deletion markedly enhanced the association of phosphorylated p100 with β-TrCP ( Figure 2D and 2E), a core E3 ubiquitin ligase for p100 ubiquitination and proteolytic processing. 31, 32 Interestingly, β-TrCP siRNA efficiently blocked the p52 upregulation in AMPKα2 −/− VSMCs ( Figure 2F ). Taken together, these data demonstrate that p52 elevation in AMPKα2-knockout VSMCs is β-TrCP dependent.
Increased Interaction of AcH3-K56 With p52 and Its Skp2 Promoter Binding Capability in AMPKα2 −/− VSMCs
Because Skp2 is upregulated in AMPKα2-knockout VSMCs via p52 activation, 9 and histone acetylation plays an important role in protein transcription, 33 we then determine the effects of AMPKα on the histone acetylation and transcription of Skp2 promoter. We assessed acetylation of core histone H3 and H4 in mouse VSMCs. Western blot with whole cell lysates demonstrated that AcH3-K56 was upregulated distinctly in AMPKα2 −/− VSMCs, but not AMPKα1 −/− VSMCs, compared with WT VSMCs (Figure 3A) , whereas AcH3-K9 or AcH4-K8 was increased in both AMPKα2 −/− and AMPKα1 −/− VSMCs. Furthermore, subcellular fractionation-validated AcH3-K56 increased in the nuclear fractions of AMPKα2 −/− VSMCs compared with WT, or AMPKα1 −/− VSMCs ( Figure 3B ). In addition, as shown in Figure 3C , AMPKα2 −/− deletion enhanced profoundly the association of p52 with AcH3-K56. This was further confirmed by immunocytochemistry, which showed increased nuclear localization of p52 and AcH3-K56 in AMPKα2 −/− VSMCs ( Figure 3D ). Importantly, chromatin immunoprecipitation analysis of the Skp2 promoter revealed that the recruitment of either p52 or AcH3-K56 to the Skp2 promoter was increased notably by AMPKα2 deletion ( Figure 3E ). These data suggest that AcH3-K56 cooperates with transcription factor p52 to upregulate Skp2 expression in AMPKα2 −/− VSMCs.
Increased AcH3-K56 in AMPKα2 −/− VSMCs Is Histone Deacetylase-3 Mediated
Histone acetylation is controlled by histone acetyltransferases and histone deacetylases (HDACs). 34 The protein level of intrinsic histone acetyltransferase, p300, 35 was downregulated in AMPKα2 −/− VSMCs ( Figure 4A ), thus p300 reduction may not contribute to the AcH3-K56 induction in AMPKα2 −/− VSMCs. Next, we investigated whether the HDACs are responsible for the increased AcH3-K56 in AMPKα2 −/− VSMCs. As depicted in Figure 4A , HDAC3, one of the class I HDACs, 36 was predominantly localized in the nucleus, which is consistent with the data reported in HEK293 cells. 37 Importantly, HDAC3 was downregulated in the nuclear fraction of AMPKα2 −/− VSMCs compared with WT or AMPKα1 −/− VSMCs ( Figure 4A ). Moreover, AMPKα2 deletion dramatically inhibited the interaction of AcH3-K56 with HDAC3 ( Figure 4B and 4C), whereas increasing the association of AcH3-K56 with HDAC5, one of the class II HDACs 38 ( Figure 4B ). These data imply that the reduction of HDAC3 and its interaction with AcH3-K56 may be responsible for the elevated level of AcH3-K56 in AMPKα2 −/− VSMCs. Consistently, overexpression of HDAC3 diminished AcH3-K56 induction in AMPKα2 −/− VSMCs ( Figure 4D ), suggesting that AcH3-K56 elevation in AMPKα2 −/− VSMCs is HDAC3 mediated. Furthermore, HDAC3 overexpression partially attenuated the enhanced cell migration of AMPKα2 −/− VSMCs ( Figure IA 
Skp2 Interacts With E-Cadherin and Promotes Its Degradation
Because E3 ubiquitin ligase Skp2 was significantly upregulated in AMPKα2 −/− VSMCs, 9 and Skp2 has been reported to function as an E3 ubiquitin ligase for E-cadherin in cancer cells by overexpression strategy, 19 we reasoned that Skp2 interacts with E-cadherin resulting in the degradation of E-cadherin in VSMCs. As depicted in Figure 5A , E-cadherin protein level was remarkably reduced in AMPKα2 −/− VSMCs, whereas increased in AMPKα1 −/− VSMCs. Paradoxically, the level of E-cadherin mRNA was elevated in AMPKα2 −/− VSMCs ( Figure 5B ). Then, it was important to test whether the reduced E-cadherin protein expression observed in AMPKα2 −/− VSMCs resulted from proteasome-mediated degradation. As shown in Figure 5C , the reduction of E-cadherin protein was partially inhibited by treatment for 8 hours with 10 μmol/L MG132, a potent inhibitor of the 26S proteasome, 39 implying a proteasome-mediated E-cadherin degradation.
The interaction between endogenous E-cadherin and Skp2 was examined by a sequential immunoprecipitation and immunoblotting assay. Endogenous E-cadherin was detected in anti-Skp2 immunoprecipitates ( Figure 5D ), and this association was confirmed in the reciprocal immunoprecipitation/immunoblotting experiment ( Figure 5E ). These results indicate that endogenous E-cadherin binds to endogenous Skp2. In addition, the interaction of Skp2 with E-cadherin in VSMCs was enhanced by AMPKα2 deletion (Figure 5E  and 5D ). Furthermore, the reduction of E-cadherin in AMPKα2 −/− VSMCs was partly but significantly attenuated by Skp2 siRNA (Figure 5F ). Taken together, these results indicate that E-cadherin is a novel Skp2-interacting protein that is downregulated by increased Skp2 expression in AMPKα2 −/− VSMCs.
Enhanced VSMC Migration by AMPKα2 Deletion Is Skp2 Dependent and E-Cadherin Mediated
By immunofluorescence assay, we further validated the reduction of E-cadherin in AMPKα2 −/− VSMCs ( Figure 6A ). The enhanced cellular migration of AMPKα2 −/− VSMCs was clearly abrogated by Skp2 siRNA ( Figure 6B ). Furthermore, p52 siRNA partially blocked the enhanced migration of AMPKα2 −/− VSMCs ( Figure IC in the online-only Data Supplement). Interestingly, E-cadherin overexpression partially attenuated Figure 6C ). These data indicated that enhanced migration of AMPKα2 −/− VSMCs is partly because of E-cadherin downregulation.
Finally, we assessed whether HDAC3, AcH3-K56, and E-cadherin levels are altered in the neointima area of AMPKα2 −/− mice. After ligation, neointima formation was enhanced in AMPKα2 −/− carotid arteries compared with both WT and AMPKα1 −/− carotid arteries ( Figure 7A and 7C) , which is consistent with wire injury model. 9 Nuclear AcH3-K56positive cells increased in the neointima of AMPKα2 −/− , but not AMPKα1 −/− , mice compared with WT animals ( Figure 7B and 7D); however, either HDAC3-positive or E-cadherin-positive cells in neointima were reduced in AMPKα2 −/− mice compared with WT or AMPKα1 −/− animals ( Figure 7B and 7D) .
Discussion
In the present study, we have shown that AMPKα2, but not AMPKα1, deletion enhances VSMC migration. Mechanistically, we found that AMPKα2 deletion triggers E-cadherin downregulation by p52-mediated and AcH3-K56-mediated upregulation of Skp2 in VSMCs ( Figure 7E ). Our results have for the first time indicated that AMPKα2 is an important mediator for both VSMC migration and proliferation, 9 as well as AMPKα2 deletion and the consequently increased proliferation and migration contribute to excessive neointima formation in vivo ( Figure 7E) .
The most important finding of this study is that AMPKα2 deletion causes aberrant VSMC migration by increasing Skp2-mediated E-cadherin downregulation. Skp2 is reported to be involved in cancer cell migration. Elevated Skp2 expression correlates significantly with metastasis of non-small-cell lung cancers to lymph nodes. 40 Here, we demonstrate that AMPKα2 deletion-augmented VSMC migration seems to depend on Skp2 upregulation, and AMPKα2 deletion suppresses E-cadherin protein level, which is reversed, in part, by proteasome inhibition (Figure 5C ). These data suggest that E-cadherin might be regulated by multiple pathways, including proteasome 20 and lysosome systems. 41 This study provides new evidence that Skp2 plays a role in modulating VSMC migration by a mechanism that involves the downregulation of E-cadherin partly through the ubiquitin proteasome pathway. This novel Skp2-mediated pathway is likely to play a biologically significant role in VSMC migration. It should be noticed that Skp2 via p27 reduction also regulates VSMC proliferation. 9 Taken together, pharmacological and recombinant technologies aimed at decreasing Skp2 may have dramatic effects on the amelioration of atherosclerosis and restenosis after angioplasty/stent placement and accelerated arteriopathy after cardiac transplantation.
Consistent with our earlier work in which we show that AMPKα2 deletion activates NF-кB2/p52 pathway, 9 here we provide molecular insights of how AMPKα2 deletion or inhibition triggers NF-кB2/p52 activation in VSMCs. For example, we found that AMPKα2 deletion increases the phosphorylation of IκB kinase-α at Ser176 and its interaction with downstream substrate p100. AMPKα2 deletion further enhances the association of phosphorylated p100 with E3 ligase β-TrCP, which mediates the p52 production from p100 processing. p52 cooperates with AcH3-K56 to upregulate Skp2 transcription. The increased AcH3-K56 seems to be mediated by HDAC3, a nuclear and cytoplasmic protein that deacetylates both histone (H2A, H3, and H4) and nonhistone substrates. 42 Recent research demonstrates that HDAC3 functions as a prosurvival factor for endothelial cells and HDAC3 knockdown instigates atherosclerosis development in response to disrupted flow. 36 Several reports indicate that AMPK regulates protein acetylation and transcription by phosphorylating HDAC5 43 and HDAC4. 44 Thus, AMPK may exert its epigenetic function via HDAC regulation, despite further investigation on the mechanism by which AMPKα2 deletion downregulates HADC3 is warranted.
Enhanced cell proliferation and migration are a common pathological mechanism for inflammatory vascular diseases, including atherosclerosis and (re)stenosis. 45 Aberrant proliferation and migration are also seen with other cells such as monocytes and macrophages. 46 Indeed, AMPKα2 deletion results in increased atherosclerosis 47 and restenosis. Thus, aberrant migration and proliferation of VSMCs, monocytes, and macrophages as a result of AMPKα2 deletion might help explain accelerated atherosclerosis in AMPKα2 −/− mice. 47 Hence, the novel signaling cascade we have unveiled may help to identify potential therapeutic targets for treating cardiovascular diseases including atherosclerosis and restenosis.
In summary, our data suggest that AMPKα2 deletion or inactivation results in aberrant VSMC migration and proliferation, 2 key events in the development and progression of vascular restenosis after vascular injury. Therefore, AMPK is likely to be a potential therapeutic target implicated in the Figure 7 . Increased histone H3 acetylation at lysine 56 (AcH3-K56) along with decreased histone deacetylase-3 (HDAC3) and E-cadherin in carotid arteries of adenosine monophosphate-activated protein kinase-α2 −/− (AMPKα2 −/− ) mice at 28 days after ligation. A, Representative sections are shown. Bar, 100 μm. B, The expression of AcH3-K56, HDAC3, and E-cadherin (brown) in ligated carotid artery. All sections were counterstained with hematoxylin to detect nuclei (blue). Bar, 50 μm. Arrow representatively indicates HDAC3-positive, AcH3-K56-positive, or E-cadherin-positive cells. C. Elevated intima/media (I/M) area ratio in AMPKα2 −/− , but not AMPKα1 −/− , mice compared with wild type (WT). n=8 in each group; *P<0.01 vs WT. D, Quantification of HDAC3-positive, AcH3-K56-positive, E-cadherin-positive cells in neointima (folds over WT). n=6 in each group; *P<0.01 vs WT. E, Proposed mechanism for enhanced vascular smooth muscle cell (VSMC) proliferation and migration in AMPKα2 −/− mice.
